January 2020 pharmaceutical M&A round-up

3 February 2020

Major acquisitions are often announced in the first month of the year, with January 2019 seeing the $74 billion acquisition of Celgene by Bristol-Myers Squibb (NYSE: BMY) and Eli Lilly's (NYSE: LLY) $8 billion purchase of Loxo Oncology.

January 2018 saw four acquisitions worth more than $1 billion announced, and there was no reason not to expect a repeat performance this year.

But the only big deal to materialize was Lilly's $1.1 billion buy of Dermira, with many commentators disappointed that this year's JP Morgan Healthcare Conference, was not the scene of more major M&A announcements.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK